Edwards Life Sciences (hereinafter referred to as Edwards) has been resolutely attending the CIIE for five consecutive years. With the theme of "Heart for You, Suffering and Rebirth", it brings more than ten cutting-edge products and treatment plans covering valve replacement and valve repair. It appeared at the CIIE and brought its global flagship product mitris resilia dry mitral valve to its "CIIE debut" after it was approved in China.
With the help of CIIE’s “acceleration”, many of Edward’s global innovative products have landed in China, accelerating the process of medical innovations benefiting Chinese patients.
At this CIIE, Edward's latest approved new generation product of the resilia tissue family - the mitris resilia mitral valve - became the biggest highlight. The world's first and currently only approved surgical mitral bioprosthetic valve that uses fully enclosed anti-calcification technology made its "new" debut at the CIIE to help patients with valve diseases achieve the full life cycle. Management offers new treatment options. As one of Edward's major events during this CIIE, the "'Rebirth, Lifelong Love' Edward Mitris Resilia Approval Celebration and Resilia Valve Roundtable" was also held at the booth.
With the debut of the mitris resilia valve, Edward's flagship series of surgical valves equipped with resilia tissue technology made a collective debut at the CIIE.
The spillover effect of the CIIE has had a positive impact on the accelerated introduction of innovation. From surgery to transcatheter interventional treatment, Edward's previous "CIIE Babies" have achieved rapid access to the Chinese market through the CIIE.
Edwards Life Sciences (hereinafter referred to as Edwards) has been resolutely attending the CIIE for five consecutive years. With the theme of "Heart for You, Suffering and Rebirth", it brings more than ten cutting-edge products and treatment plans covering valve replacement and valve repair. It appeared at the CIIE and brought its global flagship product mitris resilia dry mitral valve to its "CIIE debut" after it was approved in China.
With the help of CIIE’s “acceleration”, many of Edward’s global innovative products have landed in China, accelerating the process of medical innovations benefiting Chinese patients.
At this CIIE, Edward's latest approved new generation product of the resilia tissue family - the mitris resilia mitral valve - became the biggest highlight. The world's first and currently only approved surgical mitral bioprosthetic valve that uses fully enclosed anti-calcification technology made its "new" debut at the CIIE to help patients with valve diseases achieve the full life cycle. Management offers new treatment options. As one of Edward's major events during this CIIE, the "'Rebirth, Lifelong Love' Edward Mitris Resilia Approval Celebration and Resilia Valve Roundtable" was also held at the booth.
With the debut of the mitris resilia valve, Edward's flagship series of surgical valves equipped with resilia tissue technology made a collective debut at the CIIE.
The spillover effect of the CIIE has had a positive impact on the accelerated introduction of innovation. From surgery to transcatheter interventional treatment, Edward's previous "CIIE Babies" have achieved rapid access to the Chinese market through the CIIE.
-
-
-
-
-
-
-
-
-
-